Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Burkitt Lymphoma 35Leukemia, Myeloid, Acute 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Biphenotypic, Acute 13Leukemia, Myeloid, Accelerated Phase 11Lymphoma, Mantle-Cell 10Blast Crisis 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hodgkin Disease 9Congenital Abnormalities 9Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myelomonocytic, Chronic 8Hematologic Neoplasms 7Primary Myelofibrosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Anemia, Refractory, with Excess of Blasts 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma 4

Interventions

Cytarabine 6Vincristine 4Methotrexate 4Mercaptopurine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Thioguanine 3Dexamethasone 3Daunorubicin 3Cyclophosphamide 3Calcium Dobesilate 3Asparaginase 3prednylidene 2blinatumomab 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2Hydrocortisone 2Etoposide 2Doxorubicin 2hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Down Syndrome × merphos × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡